申请人:Wuelfing; Johann A.
公开号:US04622331A1
公开(公告)日:1986-11-11
Pharmaceutical compositions which comprise a compound of the formula (I): ##STR1## or a salt thereof wherein NR.sub.2 represents a piperidyl, pyrrolidyl, morpholino or N-methyl-piperazyl group any of which may substituted by one or two methyl groups; R.sup.1 represents fluorine, chlorine, bromine, iodine, lower alkoxyl, hydroxyl, acetoxyl, nitro, cyano, amino, dimethylamino, lower alkyl, trifluoromethyl, methylthio, ethylthio, methoxycarbonyl, ethoxycarbonyl, acetamido or carboxamido; R.sup.2 represents hydrogen, flurorine, chlorine, bromine, iodine, lower alkoxyl, hydroxyl, lower alkyl; R.sup.3 represents hydrogen, chlorine or lower alkyl; or R.sup.1 and R.sup.2 when on adjacent carbon atoms may together represent a polymethylene group containing from 3 to 5 carbon atoms; and n is 2, 3 or 4; and a pharmaceutically acceptable carrier, compounds of formula (I) except those wherein R.sup.1 is a 2-methoxyl group, and 2,4-dimethyl-1-[2-(4-bromophenylsulphonamido)ethyl]pyrrolidine and 2,4-dimethyl-1-[2-(4-bromophenylsulphonamido)ethyl]pyrrolidine, a process for the preparation of compounds of the formula (I) and 2,4-dimethyl-1-[2-(4-bromophenylsulphonamido)ethyl]pyrrolidine and 2,4-dimethyl-1-[2-(4-iodophenylsulphonamido) ethyl]pyrrolidine as anti-arrhythymic agents.
包含式(I)化合物或其盐的制药组合物,其中NR.sub.2代表
哌啶基,
吡咯烷基,吗啉基或
N-甲基哌嗪基,其中任何一个可能被一个或两个甲基取代;R.sup.1代表
氟,
氯,
溴,
碘,低碳基氧基,羟基,乙酰氧基,硝基,
氰基,
氨基,
二甲氨基,低碳基,三
氟甲基,甲
硫基,乙
硫基,甲氧基羰基,乙氧基羰基,乙酰胺基或羧酰胺基;R.sup.2代表氢,
氟,
氯,
溴,
碘,低碳基氧基,羟基,低碳基;R.sup.3代表氢,
氯或低碳基;或当R.sup.1和R.sup.2在相邻的碳原子上时,它们可能一起代表含有3到5个碳原子的聚亚甲基基团;n为2、3或4;以及制药可接受的载体,式(I)化合物除了R.sup.1为2-甲氧基基团的化合物以及2,4-二甲基-1-[2-(4-
溴苯磺酰胺)乙基]
吡咯烷和2,4-二甲基-1-[2-(4-
溴苯磺酰胺)乙基]
吡咯烷,制备式(I)化合物和2,4-二甲基-1-[2-(4-
溴苯磺酰胺)乙基]
吡咯烷和2,4-二甲基-1-[2-(4-
碘苯磺酰胺)乙基]
吡咯烷作为抗心律失常剂。